Literature DB >> 32761

Improved pacing tolerance of the ischemic human myocardium after administration of carnitine.

J H Thomsen, A L Shug, V U Yap, A K Patel, T J Karras, S L DeFelice.   

Abstract

The possibility that DL-carnitine has a protective effect during myocardial ischemia was evaluated by performing two rapid coronary sinus pacing studies 15 minutes apart in 21 patients with coronary artery disease. Eleven patients received DL-carnitine (20 or 40 mg/kg) before the second pacing study. The treated group had a significant increase in mean heart rate (12.5 beats/min, P less than 0.001), pressure-rate product (1,912 units, P less than 0.01) and pacing duration (3.2 minutes, P less than 0.001) after the administration of carnitine. The treated group also had improvements in percent myocardial lactate extraction (8.8 percent increase, P less than 0.001) and left ventricular end-diastolic pressure (a decrease of 5.3 mm Hg, P less than 0.05). There was significantly less S-T segment depression during the second pacing period in both the untreated and treated groups. The results of this study suggest that in ischemic human hearts with reasonably well preserved left ventricular function, DL-carnitine may improve the tolerance for stress associated with an increase in heart rate and pressure-rate product.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 32761     DOI: 10.1016/s0002-9149(79)80019-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

1.  Protective effects of propionyl-L-carnitine during ischemia and reperfusion.

Authors:  A Shug; D Paulson; R Subramanian; V Regitz
Journal:  Cardiovasc Drugs Ther       Date:  1991-02       Impact factor: 3.727

2.  Delineation of the influence of propionylcarnitine on the accumulation of long-chain acylcarnitines and electrophysiologic derangements evoked by hypoxia in canine myocardium.

Authors:  K A Yamada; D J Dobmeyer; E M Kanter; S G Priori; P B Corr
Journal:  Cardiovasc Drugs Ther       Date:  1991-02       Impact factor: 3.727

3.  Protective effect of propionyl-L-carnitine against ischaemia and reperfusion-damage.

Authors:  R Ferrari; C Ceconi; S Curello; E Pasini; O Visioli
Journal:  Mol Cell Biochem       Date:  1989 Jun 27-Jul 24       Impact factor: 3.396

4.  Lack of correlation between the antiarrhythmic effect of L-propionylcarnitine on reoxygenation-induced arrhythmias and its electrophysiological properties.

Authors:  M Barbieri; P U Carbonin; E Cerbai; G Gambassi; P Lo Giudice; I Masini; A Mugelli; M Pahor
Journal:  Br J Pharmacol       Date:  1991-01       Impact factor: 8.739

Review 5.  l-Carnitine. A preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism.

Authors:  K L Goa; R N Brogden
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

6.  Effects of carnitine on the ischemic arrested heart.

Authors:  D J Paulson; A L Shug
Journal:  Basic Res Cardiol       Date:  1982 Jul-Aug       Impact factor: 17.165

7.  Propionyl carnitine in stable effort angina.

Authors:  A Cherchi; C Lai; E Onnis; E Orani; R Pirisi; M R Pisano; A Soro; M Corsi
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

8.  Metabolic and physiological differences between zero-flow and low-flow myocardial ischemia: effects of L-acetylcarnitine.

Authors:  D J Paulson; M J Schmidt; J Romens; A L Shug
Journal:  Basic Res Cardiol       Date:  1984 Sep-Oct       Impact factor: 17.165

9.  Effects of some L-carnitine derivatives on heart membrane ATPases.

Authors:  N S Dhalla; F Kolár; K R Shah; R Ferrari
Journal:  Cardiovasc Drugs Ther       Date:  1991-02       Impact factor: 3.727

10.  Acyl-carnitine effects on isolated cardiac mitochondria and erythrocytes.

Authors:  M H Piper; O Sezer; P Schwartz; J F Hütter; C Schweickhardt; P G Spieckermann
Journal:  Basic Res Cardiol       Date:  1984 Mar-Apr       Impact factor: 17.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.